Erik Schneibel, MD
Cardiovascular Disease · Louisville, KYNPI 1962768721
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 21.9%. Reporting peaked in 2022 at $3,486 and has fallen 58.7% since, to $1,441 in 2025.
Across 208 payments — averaging $41.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$2K
- Abbott$1K
- Abiomed$847
- Cardiovascular Systems Inc.$801
- AstraZeneca$618
- Boston Scientific$443
- plus $3K from 20 others
What the payments were for
- Travel & lodging$3,37940%
- Food & beverage$5,04359%
- Education$1261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 12 | $1,873 |
| Abbott | 8 | $1,094 |
| Abiomed | 6 | $847 |
| Cardiovascular Systems Inc. | 6 | $801 |
| AstraZeneca | 30 | $618 |
| Boston Scientific | 9 | $443 |
| Johnson & Johnson | 26 | $372 |
| Shockwave Medical, Inc | 2 | $297 |
| Novartis | 15 | $258 |
| Amgen | 14 | $220 |
| Merck | 11 | $218 |
| Pfizer | 13 | $211 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $198 |
| Bayer | 9 | $189 |
| Medtronic(2 entities) | 2 | $176 |
| Actelion Pharmaceuticals US, Inc. | 10 | $168 |
| Esperion Therapeutics, Inc. | 4 | $144 |
| E.r. Squibb & Sons, L.L.C. | 7 | $93 |
| Astellas Pharma US Inc | 1 | $90 |
| Alnylam Pharmaceuticals Inc. | 4 | $74 |
| Kowa Pharmaceuticals America, Inc. | 3 | $35 |
| Scpharmaceuticals Inc. | 1 | $31 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $30 |
| Lantheus Medical Imaging, Inc. | 1 | $27 |
| Terumo Medical Corporation | 1 | $21 |
| Novo Nordisk | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,548 in reported general payments places this provider in the 85th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 308 | $285,140 |
| EntrestoSacubitril/Valsartan | 271 | $225,222 |
| XareltoRivaroxaban | 98 | $83,465 |
| BrilintaTicagrelor | 103 | $64,405 |
| Repatha SureclickEvolocumab | 85 | $55,495 |
| FarxigaDapagliflozin Propanediol | 38 | $24,580 |
| MultaqDronedarone Hcl | 23 | $17,640 |
| Ranolazine ErRanolazine | 110 | $14,507 |
| Praluent PenAlirocumab | 15 | $7,177 |
| Metoprolol Succinate | 392 | $5,769 |
| Amiodarone Hcl | 106 | $5,306 |
| ClopidogrelClopidogrel Bisulfate | 419 | $4,334 |
| Atorvastatin Calcium | 480 | $4,184 |
| Prasugrel Hcl | 11 | $3,827 |
| Carvedilol | 366 | $3,246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $211 | $285,140308 claims |
| NovartisEntresto | $258 | $225,222271 claims |
| AstraZenecaBrilinta, Farxiga | $618 | $88,984141 claims |
| Johnson & JohnsonXarelto | $372 | $83,46598 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Louisville
- Amir PirachaLouisville$530K
- Dinesh KalraLouisville$316K
- John HarrisLouisville$129K
- Rohan SamsonLouisville$94K
- Vipul PanchalLouisville$39K
- Steven RaibleLouisville$30K
- Chandhiran RangaswamyLouisville$19K
- Joseph LashLouisville$16K
- Shanker ChandiramaniLouisville$16K
- Pradeep SinghLouisville$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.